Monson Jonathan 4

4 · BOSTON SCIENTIFIC CORP · Filed Feb 18, 2026

AI-generated summary of this filing

Updated Feb 18, 2026

Boston Scientific (BSX) CFO Jonathan Monson Exercises RSUs; Shares Withheld

What Happened

Jonathan Monson, Executive Vice President and Chief Financial Officer of Boston Scientific (BSX), had restricted stock units (RSUs) vest/convert into 3,814 shares across Feb 13–16, 2026. The RSUs converted at $0 exercise price (code M).
To satisfy tax withholding (code F), 1,698 shares were surrendered/withheld at a reported price of $74.73 per share, generating proceeds of $126,891. Net shares delivered to Monson after withholding: 2,116 (worth about $158,129 at $74.73/share).
This was an RSU settlement with share withholding for taxes (routine compensation-related activity), not an open-market purchase or voluntary sale.

Key Details

Transaction dates and prices:
- Feb 13, 2026: 1,766 RSUs converted; 788 shares withheld for taxes at $74.73 ($58,887).
- Feb 14, 2026: 1,058 RSUs converted; 470 shares withheld at $74.73 ($35,123).
- Feb 16, 2026: 990 RSUs converted; 440 shares withheld at $74.73 ($32,881).
Total converted: 3,814 RSUs; total withheld: 1,698 shares; total withholding value: $126,891; net shares retained: 2,116.
Footnotes: F1–F4 indicate these are restricted stock units (each unit = 1 share) that vest/are issued in four equal annual installments beginning on the dates listed for the respective grants.
Shares owned after the transactions are not shown in the data provided here.
Filing timeliness: Form filed 2026-02-18 for transactions beginning 2026-02-13. This appears later than the usual two-business-day Form 4 deadline (flagged as late), which reduces immediacy of disclosure.

Context

These entries reflect conversion/settlement of RSUs and withholding of shares to cover tax obligations (a common, routine post-vesting action), not a market purchase or directional bet by the insider.
Derivative code M denotes conversion/exercise of the award; code F denotes shares withheld/surrendered to cover tax withholding (functionally similar to a cashless sale of a portion of the vested award).

Form 4

Period: 2026-02-13

EVP and CFO

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-02-13+1,766→ 37,636 total
Tax Payment
Common Stock
2026-02-13$74.73/sh−788$58,887→ 36,848 total
Exercise/Conversion
Common Stock
[F1]
2026-02-14+1,058→ 37,906 total
Tax Payment
Common Stock
2026-02-14$74.73/sh−470$35,123→ 37,436 total
Exercise/Conversion
Common Stock
[F1]
2026-02-16+990→ 38,426 total
Tax Payment
Common Stock
2026-02-16$74.73/sh−440$32,881→ 37,986 total
Exercise/Conversion
Restricted Stock Units
[F1][F2]
2026-02-13−1,766→ 5,300 total
Exp: 2029-02-13→ Common Stock (1,766 underlying)
Exercise/Conversion
Restricted Stock Units
[F1][F3]
2026-02-14−1,058→ 1,058 total
Exp: 2027-02-14→ Common Stock (1,058 underlying)
Exercise/Conversion
Restricted Stock Units
[F1][F4]
2026-02-16−990→ 0 total
Exp: 2026-02-16→ Common Stock (990 underlying)

Footnotes (4)

[F1]Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
[F2]Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.
[F3]Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.
[F4]Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.

Signature

/s/ Susan Thompson, Attorney-in-Fact|2026-02-18

1 file